State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|19|28|4875-4884

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.19, Iss.28, 2012-10, pp. : 4875-4884

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Immunoproteasome as a Therapeutic Target for Hematological Malignancies

By  

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 537-548

Bentham Science Publishers

Access to resources Recommend Favorite

Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies

By  

Current Drug Targets, Vol. 7, Iss. 10, 2006-10 ,pp. : 1341-1347

Bentham Science Publishers

Access to resources Recommend Favorite

The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies

By  

Current Cancer Drug Targets, Vol. 6, Iss. 8, 2006-01 ,pp. : 671-679

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies

By  

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 790-800

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies

By  

Current Pharmaceutical Design, Vol. 14, Iss. 21, 2008-07 ,pp. : 2040-2050

Bentham Science Publishers

Access to resources Recommend Favorite